The European life sciences investment landscape continues to shift in 2025, under the uncertain macroeconomic context. While stakeholders seem to grow more demanding and selective for young companies, innovation in life sciences remains a main appeal for investors and partners. What are the key takeaways for early-stage financing in 2025? How have investor priorities evolved, and what lessons can be learned for the year ahead? This session will provide an in-depth outlook at where capital is flowing, which types of ventures are attracting attention, and what tendencies investors are forecasting for 2026.
Sofia Arnal
Associate
AdBio Partners
